PARIS--(BUSINESS WIRE)--Regulatory News: BioAlliance Pharma SA (Paris:BIO), the specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and AIDS, today announced the initiation of its European marketing application for ondansetron RapidFilm™, the fast-dissolving oral film strip formulation of ondansetron (which until now has been used in tablet form). This innovation is designed to prevent and treat nausea and vomiting induced by chemotherapy and radiotherapy. Ondansetron RapidFilm™ facilitates administration of the drug and improves efficacy and patient compliance.
